Brokerages expect Albemarle Co. (NYSE:ALB) to report $791.46 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Albemarle’s earnings. The highest sales estimate is $811.00 million and the lowest is $777.00 million. Albemarle posted sales of $696.66 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 13.6%. The company is scheduled to announce its next quarterly earnings results after the market closes on Tuesday, February 27th.
According to Zacks, analysts expect that Albemarle will report full-year sales of $791.46 million for the current fiscal year, with estimates ranging from $2.99 billion to $3.03 billion. For the next fiscal year, analysts forecast that the company will post sales of $3.28 billion per share, with estimates ranging from $3.25 billion to $3.33 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Albemarle.
Albemarle (NYSE:ALB) last announced its earnings results on Wednesday, November 8th. The specialty chemicals company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.01. Albemarle had a net margin of 30.07% and a return on equity of 11.61%. The company had revenue of $755.00 million during the quarter, compared to analyst estimates of $732.19 million. During the same period in the previous year, the business earned $0.91 earnings per share. The firm’s quarterly revenue was up 15.4% compared to the same quarter last year.
Hedge funds have recently added to or reduced their stakes in the stock. Lord Abbett & CO. LLC bought a new position in Albemarle in the second quarter worth about $11,681,000. Sumitomo Life Insurance Co. bought a new position in Albemarle in the third quarter worth about $1,703,000. Hardman Johnston Global Advisors LLC raised its stake in Albemarle by 1.9% in the third quarter. Hardman Johnston Global Advisors LLC now owns 285,837 shares of the specialty chemicals company’s stock worth $38,962,000 after buying an additional 5,430 shares in the last quarter. Advisory Services Network LLC raised its stake in Albemarle by 43.7% in the second quarter. Advisory Services Network LLC now owns 1,273 shares of the specialty chemicals company’s stock worth $134,000 after buying an additional 387 shares in the last quarter. Finally, Allianz Asset Management GmbH raised its stake in Albemarle by 98.8% in the third quarter. Allianz Asset Management GmbH now owns 1,307,904 shares of the specialty chemicals company’s stock worth $178,281,000 after buying an additional 650,158 shares in the last quarter. 88.16% of the stock is owned by institutional investors.
Shares of Albemarle (NYSE:ALB) opened at $106.63 on Thursday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.56 and a current ratio of 2.11. Albemarle has a 1 year low of $90.35 and a 1 year high of $144.99. The stock has a market cap of $11,780.00, a PE ratio of 38.08, a price-to-earnings-growth ratio of 1.38 and a beta of 1.56.
TRADEMARK VIOLATION WARNING: “Zacks: Analysts Expect Albemarle Co. (ALB) Will Post Quarterly Sales of $791.46 Million” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/08/zacks-analysts-expect-albemarle-co-alb-will-post-quarterly-sales-of-791-46-million.html.
Albemarle Company Profile
Albemarle Corporation is a global developer, manufacturer and marketer of highly-engineered specialty chemicals. The Company operates through three segments: Lithium and Advanced Materials, Bromine Specialties and Refining Solutions. Lithium and Advanced Materials segment consist of two product categories: Lithium and Performance Catalyst Solutions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.